Bolder BioTechnology, Inc. announced that it has been awarded a
$99,000 Phase I Small Business Innovation Research (SBIR) grant from
the National Institute of Allergy and Infectious Diseases (NIAID) of
The National Institutes of Health. The grant supports research to
improve the pharmacological properties of a human protein, gamma
interferon, to enhance its ability to stimulate the body's immune
system to fight infections. The optimized gamma interferon protein
may prove useful for the treatment of viral infections,
immunodeficiencies and various cancers.

Bolder BioTechnology, Inc. announced that it has been awarded a
$99,000 Phase I Small Business Innovation Research (SBIR) grant from
the National Institute of Allergy and Infectious Diseases (NIAID) of
The National Institutes of Health. The grant supports research to
improve the pharmacological properties of a human protein, gamma
interferon, to enhance its ability to stimulate the body's immune
system to fight infections. The optimized gamma interferon protein
may prove useful for the treatment of viral infections,
immunodeficiencies and various cancers.

The SBIR program is a peer-reviewed grant program that provides
research support to small businesses to discover and develop
innovative biomedical products for the treatment of serious unmet
medical needs. Companies that successfully meet the goals of the
Phase I grant are eligible to apply for an additional $750,000 in
Phase II grant support to continue their product development efforts.

Bolder BioTechnology, Inc. uses advanced protein engineering
technologies to create proprietary, long-acting human protein
pharmaceuticals for the treatment of hematopoietic and endocrine
disorders, cancer and infectious diseases. For additional
information about Bolder BioTechnology, Inc., please visit our web
site at http://www.bolderbio.com/.

Statements contained herein that are not historical facts are
forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that
could cause actual results to differ materially from those expressed
in any forward-looking statements made by the Company. These factors
include, but are not limited to: (1) the Company's ability to
successfully complete product research and development, including
pre-clinical and clinical studies, and commercialization; (2) the
Company's ability to obtain required government approvals; (3) the
Company's ability to attract and/or maintain manufacturing, sales,
distribution and marketing partners; and (4) the Company's ability
to develop and commercialize its products before its competitors.

Web site: http://www.bolderbio.com/

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech